Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

NCT02891850 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Riociguat (Adempas, BAY63-2521)
DRUG: Sildenafil
DRUG: Tadalafil

Sponsor

Bayer